GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
F

Faron Pharmaceuticals Oy FARN.L · GBp

Health Care · LSE · 🇬🇧 United Kingdom

Compare

29.00p

0.00%

Close of 9 Nov 2026, in pence

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

Faron Pharmaceuticals Oy — daily FARN

No embeddable chart for this listing. TradingView's free widgets do not cover this exchange, and an unsupported symbol would render an error panel rather than a chart.

View Faron Pharmaceuticals Oy on TradingView ↗
Market value
£33.6m
Last close × shares
Volume
7.2k
Shares, 9 Nov 2026

About Faron Pharmaceuticals Oy

Its shares trade on LSE under the ticker FARN.L. It has been listed since 17 November 2015. In the fiscal year to 31 December 2018, it reported revenue of €19,000 and a net loss of €20.1m. At that date it held total assets of €8.0m and shareholders' equity of €369,000.

Faron Pharmaceuticals Oy is a clinical stage biopharmaceutical company. The company is headquartered in Turku, Lansi-Suomen. The company went IPO on 2015-11-17. The Company’s pipeline is based on endothelial receptors involved in regulation of immune responses and focuses on acute organ traumas, vascular damage and cancer immunotherapy. The firm has two technological platforms: Traumakine and Clevegen. Traumakine aims to prevent vascular leakage and organ failure under ischemic condition. The company is undergoing Phase III clinical trials for the treatment of Acute Respiratory Distress Syndrome (ARDS) and European Phase II trial for the prevention of multi-organ failure after emergency aortic surgery for a Rupture of Abdominal Aorta Aneurysm (RAAA). Clevegen is a ground breaking early clinical anti-Clever-1 antibody able to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development. The company may be used alone or in combination with other immune checkpoint molecules.

Figures and description from our data supplier, not checked against the company's own report.

More about Faron Pharmaceuticals Oy →

Latest on Faron Pharmaceuticals Oy

Our reporting

We have not reported on Faron Pharmaceuticals Oy yet.

Next results

19 Mar 2027

Due on 19 Mar 2027. Analysts expect earnings of -0.04 a share.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is Faron Pharmaceuticals Oy's ticker?

Faron Pharmaceuticals Oy trades as FARN.L on LSE, under ISIN FI4000153309.

What was Faron Pharmaceuticals Oy's last closing price?

29.00p on 9 Nov 2026. The figure is in GBp and is never converted.

When does Faron Pharmaceuticals Oy next report results?

Results are expected on 19 Mar 2027, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
Our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.